This article is more than 5 years old. Information may no longer be current.
Lpath initiates phase 1 trial of retinal disease drug candidate
SAN DIEGO — Lpath has initiated dosing for a phase 1 clinical trial evaluating the efficacy of a compound for treating age-related macular degeneration and possibly other ocular diseases, the company announced in a press release.
The drug, called iSONEP, is a monoclonal sphingosine-1-phosphate (S1P) antibody that has demonstrated anti-angiogenic, anti-inflammatory, anti-vascular permeability and anti-fibrosis mechanisms of action in various animal models of retinal disease, according to the release.
"[This] represents the first time a patient has received an intraocular antibody that inhibits a bioactive lipid, and it also represents the first time a company has targeted the S1P pathway in a clinical trial for AMD," Roger Sabbadini, PhD, founder and chief scientific officer of Lpath, said in the release.